309 related articles for article (PubMed ID: 30223804)
21. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
Bret P; Bret MC; Queuille E
Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
[TBL] [Abstract][Full Text] [Related]
22. Descriptions and Correlates of Medication Adherence, Attitudes, and Self-Efficacy in Outpatients With Schizophrenia Spectrum Disorders (SSDs).
Beebe LH; Smith K; Phillips C
Arch Psychiatr Nurs; 2016 Jun; 30(3):400-5. PubMed ID: 27256948
[TBL] [Abstract][Full Text] [Related]
23. Negative impact of self-stigmatization on attitude toward medication adherence in patients with psychosis.
Uhlmann C; Kaehler J; Harris MS; Unser J; Arolt V; Lencer R
J Psychiatr Pract; 2014 Sep; 20(5):405-10. PubMed ID: 25226204
[TBL] [Abstract][Full Text] [Related]
24. The role of atypical antipsychotic agents in the treatment of schizophrenia and schizoaffective disorders in the elderly.
Madhusoodanan S; Sinha A; Sajatovic M; Gupta S; Brenner R
Curr Drug Saf; 2006 Aug; 1(3):227-41. PubMed ID: 18690933
[TBL] [Abstract][Full Text] [Related]
25. Patients' Knowledge about Prescribed Antipsychotics and Medication Adherence in Schizophrenia: A Cross-Sectional Survey.
Nagai N; Tani H; Suzuki T; Ikai S; Gerretsen P; Mimura M; Uchida H
Pharmacopsychiatry; 2017 Nov; 50(6):264-269. PubMed ID: 28675911
[No Abstract] [Full Text] [Related]
26. The effect of providing patient-specific electronically monitored antipsychotic medication adherence results on the treatment planning of prescribers of outpatients with schizophrenia.
Nakonezny PA; Byerly MJ; Pradhan A
Psychiatry Res; 2013 Jun; 208(1):9-14. PubMed ID: 23473653
[TBL] [Abstract][Full Text] [Related]
27. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.
Kane JM; Leucht S; Carpenter D; Docherty JP;
J Clin Psychiatry; 2003; 64 Suppl 12():5-19. PubMed ID: 14640142
[TBL] [Abstract][Full Text] [Related]
28. Attitudes toward antipsychotic medications as a useful feature in exploring medication non-adherence in schizophrenia.
Samalin L; de Chazeron I; Blanc O; Brunel L; Fond G; Llorca PM
Schizophr Res; 2016 Dec; 178(1-3):1-5. PubMed ID: 27637362
[TBL] [Abstract][Full Text] [Related]
29. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
Popović I; Ravanić D; Popović V; Vladejić S; Stanojević A; Stojanović M
Psychiatr Danub; 2011 Dec; 23(4):384-8. PubMed ID: 22075740
[TBL] [Abstract][Full Text] [Related]
30. Decision-making Capacity for Treatment of Psychotic Patients on Long Acting Injectable Antipsychotic Treatment.
Nystazaki M; Pikouli K; Tsapakis EM; Karanikola M; Ploumpidis D; Alevizopoulos G
Arch Psychiatr Nurs; 2018 Apr; 32(2):300-304. PubMed ID: 29579528
[TBL] [Abstract][Full Text] [Related]
31. [Successful quetiapine therapy in psychotic patients with mood elevation].
Kecskés I
Neuropsychopharmacol Hung; 2009 Dec; 11(4):259-63. PubMed ID: 20150663
[TBL] [Abstract][Full Text] [Related]
32. A trial of compliance therapy in outpatients with schizophrenia or schizoaffective disorder.
Byerly MJ; Fisher R; Carmody T; Rush AJ
J Clin Psychiatry; 2005 Aug; 66(8):997-1001. PubMed ID: 16086614
[TBL] [Abstract][Full Text] [Related]
33. Effects of antipsychotic polypharmacy on side-effects and concurrent use of medications in schizophrenic outpatients.
Hashimoto Y; Uno J; Miwa T; Kurihara M; Tanifuji H; Tensho M
Psychiatry Clin Neurosci; 2012 Aug; 66(5):405-10. PubMed ID: 22834658
[TBL] [Abstract][Full Text] [Related]
34. Strategies for improving treatment adherence in schizophrenia and schizoaffective disorder.
Goff DC; Hill M; Freudenreich O
J Clin Psychiatry; 2010; 71 Suppl 2():20-6. PubMed ID: 21190649
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of factors influencing medication compliance in inpatient treatment of psychotic disorders.
Janssen B; Gaebel W; Haerter M; Komaharadi F; Lindel B; Weinmann S
Psychopharmacology (Berl); 2006 Aug; 187(2):229-36. PubMed ID: 16710714
[TBL] [Abstract][Full Text] [Related]
36. The risks and benefits of switching patients with schizophrenia or schizoaffective disorder from two to one antipsychotic medication: a randomized controlled trial.
Constantine RJ; Andel R; McPherson M; Tandon R
Schizophr Res; 2015 Aug; 166(1-3):194-200. PubMed ID: 26141142
[TBL] [Abstract][Full Text] [Related]
37. Antipsychotics side effects' influence on stigma of mental illness: focus group study results.
Novak L; Svab V
Psychiatr Danub; 2009 Mar; 21(1):99-102. PubMed ID: 19270631
[TBL] [Abstract][Full Text] [Related]
38. Aripiprazole in schizophrenia and schizoaffective disorder: A review.
Stip E; Tourjman V
Clin Ther; 2010; 32 Suppl 1():S3-20. PubMed ID: 20152550
[TBL] [Abstract][Full Text] [Related]
39. The Effects of Psychoeducation on Long-term Inpatients with Schizophrenia and Schizoaffective Disorder.
Yanagida N; Uchino T; Uchimura N
Kurume Med J; 2017 May; 63(3.4):61-67. PubMed ID: 28381728
[TBL] [Abstract][Full Text] [Related]
40. The schizophrenia PORT pharmacological treatment recommendations: conformance and implications for symptoms and functional outcome.
Buchanan RW; Kreyenbuhl J; Zito JM; Lehman A
Schizophr Bull; 2002; 28(1):63-73. PubMed ID: 12047023
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
